Projected Earnings Date: 2024-08-23    (Delayed quote data   2025-01-06)
Last
 4.34
Change
 ⇑ +0.08   (+1.88%)
Volume
  40,502
Open
 4.26
High
 4.48
Low
 4.13
8EMA (Daily)
 4.26
40EMA (Daily)
 4.91
50EMA (Daily)
 4.99
STO (Daily)
 21.733
MACD Hist (Daily)
 -0.043
8EMA (Weekly)
 4.763
40EMA (Weekly)
 4.91
50EMA (Weekly)
 4.79
STO (Weekly)
 12.592
MACD Hist (Weekly)
 -0.414
Dermira Inc is a biopharmaceutical company focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States.The company's late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne.
optionchance optionchance
Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2025 OptionChance.com